nulibry
(fosdenopterin hydrobromide)Sentynl Therapeutics, Inc.
Usage: NULIBRY is indicated for reducing the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.
Sentynl Therapeutics, Inc. drugs
3 results
zokinvy - lonafarnib capsule
(Lonafarnib)Sentynl Therapeutics, Inc.zycubo
(Copper Histidinate)Sentynl Therapeutics, Inc.